查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1611965

無細胞療法市場：按框架和應用分類－2025年至2030年全球預測

Acellular Therapy Market by Scaffold (Cell Laden Hydrogel, Extracellular Matrix (ECM), Fused Deposition Modeling (FDM)), Application (Cardiology, Gastroenterology, Hepatology) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

無細胞治療市場2023年估值為110.7億美元，預計2024年將達到124.9億美元，複合年成長率為13.37%，到2030年將達到266.5億美元。

無細胞療法是再生醫學的前沿領域，利用細胞外基質、生長因子和細胞激素等無細胞成分來促進組織修復和再生。無細胞療法的需求源於解決傳統細胞療法帶來免疫風險或不切實際的疾病狀態的潛力。其應用範圍從創傷治療和整形外科修復到心血管和神經治療。主要的最終用途領域包括醫院、研究機構和門診手術中心。市場成長的主要驅動力是技術進步、意識提高和慢性病的增加。個人化醫療方法以及透過奈米技術整合細胞成分以增強遞送和功效的機會比比皆是。公司可以透過投資研發合作夥伴關係和研究合作來利用這些趨勢，旨在開發針對特定醫療條件的解決方案。

主要市場統計
基準年[2023] 110.7億美元
預計年份 [2024] 124.9億美元
預測年份 [2030] 266.5億美元
複合年成長率（%） 13.37%

然而，一些挑戰正在影響市場的成長。監管障礙仍然是一個主要問題，因為細胞培養療法有時需要更廣泛的檢驗和標準化流程。人們對長期療效有一些懷疑，需要全面的臨床測試和資料來獲得相關人員的信心。此外，與研發相關的高成本以及製造的複雜性可能會阻止新進入者並影響整體市場競爭。

創新的最佳途徑是開發能夠模仿自然組織環境並與人體生理學更好地融合的新型生物材料。專注於提高細胞成分在儲存和運輸過程中的穩定性和生物活性的研究部分對於傳播至關重要。了解市場動態表明，北美和歐洲由於其發達的醫療基礎設施而具有主導成長軌跡，而亞太地區由於醫療投資的增加而具有更大的潛力。企業應專注於透過夥伴關係關係制定適應性策略，並開拓開拓的區域市場，以在不斷變化的環境中保持競爭力。

市場動態：揭示快速發展的無細胞治療市場的關鍵市場洞察

無細胞治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 慢性病和與老齡化相關的疾病盛行率增加
    • 政府推動再生醫學和幹細胞研究的舉措
    • 增加無細胞和智慧生物材料的可用性
  • 市場限制因素
    • 缺乏熟練的研究人員和有限的報銷選擇
  • 市場機會
    • 全球無細胞療法進展及研發
    • 本院及醫療機構無細胞治療計劃增多
  • 市場問題
    • 有關再生醫學和細胞治療的複雜法規

波特五力：駕馭無細胞治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解對無細胞治療市場的外部影響

外部宏觀環境因素在塑造非細胞治療市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解無細胞治療市場的競爭格局

對無細胞治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：無細胞治療市場供應商的績效評估

FPNV定位矩陣是評估無細胞治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製無細胞治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對無細胞治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病和與老齡化相關的疾病增加
      • 政府推動再生醫學和幹細胞研究的舉措
      • 提高無細胞和智慧生物材料的可用性
    • 抑制因素
      • 缺乏熟練的研究人員和有限的報銷選擇
    • 機會
      • 全球無細胞療法的進展與研發
      • 醫院和醫療機構實施的無細胞治療計劃增加
    • 任務
      • 有關再生醫學和無細胞療法的複雜法規
  • 市場區隔分析
    • 骨骼：細胞外基質支持的優先非細胞治療
    • 應用：開發腫瘤學中針對腫瘤部位的無細胞療法
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章無細胞治療市場：透過支架

  • 介紹
  • 含細胞水凝膠
  • 細胞外基質（ECM）
  • 熔融沈積建模 (FDM)

第7章無細胞治療市場：依應用分類

  • 介紹
  • 心臟病學
  • 胃腸病學
  • 肝病學
  • 神經病學
  • 腫瘤學

第8章美洲無細胞治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太無細胞治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲的無細胞治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Humacyte 宣佈人類無細胞血管 (HAV) 治療血管創傷患者的 2/3 期試驗取得正面結果
    • FDA核准細胞療法 Lantidra 用於治療第 1 型糖尿病
    • Humacyte 向烏克蘭前線醫院提供人類去細胞血管（HAV），用於治療血管創傷
  • 戰略分析和建議

公司名單

  • Allergan Inc. by Abbvie Inc.
  • AlloSource
  • Aziyo Biologics
  • Baxter International
  • Becton, Dickinson and Company
  • BioHorizons, Inc.
  • EnColl Corporation
  • Engitix Ltd
  • Fidia Farmaceutici SpA
  • GSK PLC
  • Humacyte, Inc.
  • In2Bones Global by CONMED Corporation
  • Integra LifeSciences Corporation
  • LifeNet Health
  • MiMedx Group
  • Organicell Regenerative Medicine, Inc.
  • Organogenesis Holdings Inc.
  • Reprise Biomedical, Inc.
  • Sanofi SA
  • Smith & Nephew PLC
  • Stryker Corporation
  • Tissue Regenix
  • Vascudyne, Inc.
  • Zimmer Biomet
Product Code: MRR-5A3042B3D68D

The Acellular Therapy Market was valued at USD 11.07 billion in 2023, expected to reach USD 12.49 billion in 2024, and is projected to grow at a CAGR of 13.37%, to USD 26.65 billion by 2030.

Acellular therapy, a cutting-edge segment within regenerative medicine, involves using cell-free components such as extracellular matrix, growth factors, and cytokines to promote tissue repair and regeneration. The necessity for acellular therapy arises from its potential to address conditions where traditional cellular therapies may introduce immunological risks or be impractical. Applications are vast, ranging from wound healing and orthopedic repairs to cardiovascular and neurological therapy. Key end-use segments include hospitals, research institutes, and ambulatory surgical centers. Market growth is largely driven by technological advancements, increasing awareness, and a rise in chronic disease prevalence. Opportunities abound in personalized medicine approaches and integrating acellular components with nanotechnology for enhanced delivery and efficacy. Companies can capitalize on these trends by investing in R&D partnerships and collaborations aimed at developing tailored solutions for specific medical conditions.

KEY MARKET STATISTICS
Base Year [2023] USD 11.07 billion
Estimated Year [2024] USD 12.49 billion
Forecast Year [2030] USD 26.65 billion
CAGR (%) 13.37%

However, several challenges affect market progression. Regulatory hurdles remain a significant concern as acellular therapies, in some cases, need more extensive validation and standardization processes. Skepticism exists around long-term efficacy, pushing the need for comprehensive clinical trials and data to gain stakeholder confidence. Additionally, high costs associated with R&D, alongside manufacturing complexities, can hinder entry for new players, affecting overall market competition.

Innovations are best pursued in the development of novel biomaterials that can mimic natural tissue environments and achieve better integration with human physiology. Research areas focusing on improving the stability and bioactivity of acellular components during storage and transport will be critical for widespread implementation. Understanding market dynamics reveals a growth trajectory dominated by North America and Europe due to their developed healthcare infrastructure, while Asia-Pacific shows immense potential due to increasing healthcare investments. Businesses should focus on building adaptive strategies leveraging partnerships and exploring untapped regional markets to maintain a competitive edge in this evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acellular Therapy Market

The Acellular Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of chronic diseases and age-related conditions
    • Government initiatives to propel regenerative medicine and stem cell research
    • Increased availability of acellular and smart biomaterials
  • Market Restraints
    • Lack of skilled research personnel and limited reimbursement options
  • Market Opportunities
    • Advancements and R&D in acellular therapy worldwide
    • Rising number of acellular therapy projects undertaken by hospitals and medical entities
  • Market Challenges
    • Complex regulations pertaining to regenerative medicine and acellular therapies

Porter's Five Forces: A Strategic Tool for Navigating the Acellular Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acellular Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acellular Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acellular Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acellular Therapy Market

A detailed market share analysis in the Acellular Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acellular Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acellular Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acellular Therapy Market

A strategic analysis of the Acellular Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acellular Therapy Market, highlighting leading vendors and their innovative profiles. These include Allergan Inc. by Abbvie Inc., AlloSource, Aziyo Biologics, Baxter International, Becton, Dickinson and Company, BioHorizons, Inc., EnColl Corporation, Engitix Ltd, Fidia Farmaceutici S.p.A, GSK PLC, Humacyte, Inc., In2Bones Global by CONMED Corporation, Integra LifeSciences Corporation, LifeNet Health, MiMedx Group, Organicell Regenerative Medicine, Inc., Organogenesis Holdings Inc., Reprise Biomedical, Inc., Sanofi S.A., Smith & Nephew PLC, Stryker Corporation, Tissue Regenix, Vascudyne, Inc., and Zimmer Biomet.

Market Segmentation & Coverage

This research report categorizes the Acellular Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Scaffold, market is studied across Cell Laden Hydrogel, Extracellular Matrix (ECM), and Fused Deposition Modeling (FDM).
  • Based on Application, market is studied across Cardiology, Gastroenterology, Hepatology, Neurology, and Oncology.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of chronic diseases and age-related conditions
      • 5.1.1.2. Government initiatives to propel regenerative medicine and stem cell research
      • 5.1.1.3. Increased availability of acellular and smart biomaterials
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of skilled research personnel and limited reimbursement options
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and R&D in acellular therapy worldwide
      • 5.1.3.2. Rising number of acellular therapy projects undertaken by hospitals and medical entities
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulations pertaining to regenerative medicine and acellular therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Scaffold: Preference for extracellular matrix to support acellular therapy
    • 5.2.2. Application: Development of acellular therapy designed to target oncology tumor sites
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acellular Therapy Market, by Scaffold

  • 6.1. Introduction
  • 6.2. Cell Laden Hydrogel
  • 6.3. Extracellular Matrix (ECM)
  • 6.4. Fused Deposition Modeling (FDM)

7. Acellular Therapy Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiology
  • 7.3. Gastroenterology
  • 7.4. Hepatology
  • 7.5. Neurology
  • 7.6. Oncology

8. Americas Acellular Therapy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Acellular Therapy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Acellular Therapy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Humacyte Announces Positive Top-Line Results from Phase 2/3 Trial of Human Acellular Vessel (HAV) in Treatment of Patients with Vascular Trauma
    • 11.3.2. FDA Approves Lantidra, a Cellular Therapy for Type 1 Diabetes
    • 11.3.3. Humacyte to Provide Human Acellular Vessels (HAVs) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Allergan Inc. by Abbvie Inc.
  • 2. AlloSource
  • 3. Aziyo Biologics
  • 4. Baxter International
  • 5. Becton, Dickinson and Company
  • 6. BioHorizons, Inc.
  • 7. EnColl Corporation
  • 8. Engitix Ltd
  • 9. Fidia Farmaceutici S.p.A
  • 10. GSK PLC
  • 11. Humacyte, Inc.
  • 12. In2Bones Global by CONMED Corporation
  • 13. Integra LifeSciences Corporation
  • 14. LifeNet Health
  • 15. MiMedx Group
  • 16. Organicell Regenerative Medicine, Inc.
  • 17. Organogenesis Holdings Inc.
  • 18. Reprise Biomedical, Inc.
  • 19. Sanofi S.A.
  • 20. Smith & Nephew PLC
  • 21. Stryker Corporation
  • 22. Tissue Regenix
  • 23. Vascudyne, Inc.
  • 24. Zimmer Biomet

LIST OF FIGURES

  • FIGURE 1. ACELLULAR THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. ACELLULAR THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACELLULAR THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACELLULAR THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACELLULAR THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACELLULAR THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CELL LADEN HYDROGEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY EXTRACELLULAR MATRIX (ECM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY FUSED DEPOSITION MODELING (FDM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY HEPATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023